Clinical trial NCT02218996: Treatment of Anxiety Disorders for Children and Adolescents in Regular Outpatient Clinics
Official title: Treatment of Anxiety Disorders for Children and Adolescents in Regular Outpatient Clinics (TADCAROC)
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Anxiety Disorders
Keywords: Anxiety
Children
Adolescent
Effectiveness
Outpatient
Lead sponsor: Helse Stavanger HF
Sponsor class: OTHER_GOV
Collaborators: name: Helse Vest
First posted: 2014-08-18
Enrollment: 260
Sex: ALL
Minimum age (years): 7
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children/adolescents from 7-17 years old referred to ordinary outpatient mental health service.

Brief summary: The purpose of this study is to examine the content of the treatment being delivered for anxiety disorders for children and adolescents in the regular outpatient clinics in western Norway. The study will also collect data before and after treatment to evaluate the result of the treatment. Furthermore, as part of the study we aim to collect normative data on two questionnaires used to identify anxiety symptoms and the extent to which anxiety interfere with daily functioning. We also aim to develop a quality indicator for anxiety treatment that can be used to monitor treatment in the regular outpatient service, based on the results of the current study.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of an anxiety disorder (including PTSD and OCD) based on the diagnostic interview ADIS (ADIS-C/P; Silverman \& Albano, 1996).
* The anxiety disorder is the patients primary diagnosis.
* Informed concent is given.

Exclusion Criteria:

* The patient is in need for other primary treatment intervention (e.g., psychosis, suicidality risk)

Primary outcomes:
measure: The Anxiety Disorder Interview Schedule for Diagnostic and Statistical Manual (DSM-IV), child and parent versions (ADIS- C/P; Silverman & Albano, 1996).
timeFrame: The primary outcome measure will be administered pre-treatment, post treatment (an expected average of 20 weeks) and at ten year follow-up.
Secondary outcomes:
measure: Children's Anxiety Life Interference Scale (CALIS; Lyneham et al., 2013)
timeFrame: This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks).
measure: The Screen for Child Anxiety Related Emotional Disorders (SCARED; Birmaher et al., 1999).
timeFrame: This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks).
measure: Spence Children's Anxiety Scale (SCAS; Spence, 1998)
timeFrame: This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks).
measure: The Strengths and Difficulties Questionnaire (SDQ; Goodman, 1997)
timeFrame: This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks)
measure: Short Mood & Feeling Questionaire (SMFQ; Angold et al., 1995).
timeFrame: This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks)
measure: Clinical Global Impressions (CGI; Guy, 1976).
timeFrame: The outcome measure will be administered pre-treatment, post treatment (an expected average of 20 weeks) and at ten year follow-up.
Other outcomes:
Locations:
city: Stavanger
country: Norway
facility: BUPA Helse Stavanger
state: Rogaland
Study officials:
affiliation: Division of Psychiatry, Stavanger University Hospital, N-4068 Stavanger, Norway
name: Jon F Bjaastad, D. Psych
role: PRINCIPAL_INVESTIGATOR
References: